This video briefly summarizes the 12 month treat-and-extend use of aflibercept in neovascular age-related macular degeneration in naive patients presented at this year’s EURETINA congress, held in Copenhagen, Denmark (Thursday 8 September 2016, 09:06-09:12). A total of 169 eyes treated with aflibercept in a treat-and-extend regime with 1-year follow-up was examined. Investigators Barthelmes et al. from Switzerland found that after 1 year there was an average of +9.5 letter increase in visual acuity, mean visual acuity gains after the initial 6 months of treatment was recorded at +9.1 letters compared with +0.4 in the following 6 months. There was an overall mean of 7.3 injections over the 12 months with 4.6 injections in the first 6 months and 2.7 in the second 6 months. Mean number of visits was 7.8 over the 12 months, 4.8 visits in the first 6 months and 3.0 in the second 6 months. Injections were given in 86% of all visits within the 12-month follow-up period. The study demonstrated that eyes treated with aflibercept in routine clinical practice under a treat and extend regiment achieve good visual outcomes for the first 12 months while decreasing the burden of treatments and clinic visits compared to the pivotal monthly injection trials.

Related Articles